147283-46-3

Upstream product

• 2142-68-9 1-(2-chlorophenyl)ethanone 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 107-91-5 cyanoacetic acid amide 
• 75175-78-9 1-(2-chlorophenyl)-3-(dimethylamino)prop-2-en-1-one 

Downstream Products

• 1065267-37-9 5-bromo-6-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 1160912-87-7 C₁₂H₅BrCl₂N₂ 
• 1065267-41-5 6-bromo-2-tert-butyl-7-(2-chlorophenyl)-8,8a-dihydropyrido[2,3-d]pyrimidin-4-amine 
• 1065267-44-8 6-bromo-2-tert-butyl-7-(2-chlorophenyl)-8,8a-dihydropyrido[2,3-d]pyrimidin-4(3H)-one 
• 1065267-48-2 6-bromo-2-tert-butyl-4-chloro-7-(2-chlorophenyl)-8,8a-dihydropyrido[2,3-d]pyrimidine 
• 1065267-53-9 6-bromo-2-tert-butyl-7-(2-chlorophenyl)-4-hydrazino-8,8a-dihydropyrido[2,3-d]pyrimidine 
• 1065267-31-3 9-bromo-5-tert-butyl-8-(2-chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one 
• 1065266-64-9 9-(4-acetylphenyl)-5-tert-butyl-8-(2-chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one 
• 147313-49-3 2-[3-benzyloxycarbonylamino-6-(2-chlorophenyl)-2-oxo-1,2-dihydro-1-pyridyl]-N-(2-tert-butyldimethylsilyloxy-3,3,3-trifluoro-1-isopropylpropyl)acetamide 
• 147283-48-5 2-[3-benzyloxycarbonylamino-6-(2-chlorophenyl)-2-oxo-1,2-dihydro-1-pyridyl]-N-(3,3,3-trifluoro-2-hydroxy-1-isopropylpropyl)acetamide 
• 147313-48-2 benzyl 6-(2-chlorophenyl)-2-oxo-1,2-dihydropyridin-3-ylcarbamate 
• 147267-17-2 2-<3-<(benzyloxycarbonyl)amino>-2-oxo-6-phenyl-1,2-dihydro-1-pyridyl>-N-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)acetamide 
• 147269-02-1 2-<3-<(benzyloxycarbonyl)amino>-2-oxo-6-phenyl-1,2-dihydro-1-pyridyl>-N-<2-<(tert-butyldimethylsilyl)oxy>-3,3,3-trifluoro-1-isopropylpropyl>acetamide 
• 147269-03-2 2-<3-<(benzyloxycarbonyl)amino>-2-oxo-6-phenyl-1,2-dihydro-1-pyridyl>-N-(3,3,3-trifluoro-2-hydroxy-1-isopropylpropyl)acetamide 

Relevant academic research and scientific papers

Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation

The synthesis, SAR and binding affinities are described for cannabinoid-1 receptor (CB1R) specific inverse agonists based on pyridopyrimidine and heterotricyclic scaffolds. Food intake and pharmacokinetic evaluation of several of these compounds indicate

SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present in

Nonpeptidic inhibitors of human leukocyte elastase. 2. Design, synthesis, and in vitro activity of a series of 3-amino-6-arylopyridin-2-one trifluoromethyl ketones

A series of potent nonpeptidic inhibitors of the enzyme human leukocyte elastase (HLE) is reported. These inhibitors contain a 3-amino-2-pyridone ring as a central template in which the pyridone carbonyl and 3-position NH group are thought to form important hydrogen bonding interactions with the Val-216 residue of HLE. Substitution of the 6-position of the pyridone ring by various alkyl and aryl groups was found to afford increases in the in vitro potency of these inhibitors. A 6-position phenyl group, compound 10f, was found to result in a large increase in binding affinity, which was not obtained when the phenyl group was placed in either the 4- or 5-position of the molecule. Compound 10f was found to have good selectivity for HLE over other proteolytic enzymes, with the exception of bovine pancreatic chymotrypsin (BPC). Substitution of the 6-phenyl group in these molecules was found to decrease binding affinity for BPC without adversely affecting affinity for HLE.